Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This study will combine a standard, pediatric-inspired, chemotherapy regimen with the tyrosine kinase inhibitors (TKIs) Dasatinib and Ponatinib to treat adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

There are two age groups/cohorts:

• participants aged 18 to 59 years
• participants aged 60 years and older

One tyrosine kinase inhibitor (TKI), either Dasatinib or Ponatinib, will be administered in each of the respective chemotherapy cycles. The TKI (either Dasatinib or Ponatinib) administered in a given cycle of chemotherapy will be dictated by the given cycle's standard chemotherapy, in order to minimize overlapping side effects of the chemotherapy and TKI.

The dosages of the standard chemotherapy agents, as well as the tyrosine kinase inhibitors (TKIs)--Dasatinib and Ponatinib--have been adjusted for each age group to allow continuous administration of these TKIs.

Study Overview

• Status: Withdrawn
• Conditions: Acute Lymphoblastic Leukemia
• Intervention / Treatment: Drug: Dasatinib; Drug: Ponatinib; Drug: Berlin-Frankfurt-Münster Chemotherapy; Drug: Methotrexate and Cytarabine

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • University of Michigan Rogel Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria

• Patients ≥ 18 years of age.
• Baseline ECOG Performance Status ≤ 2, and patient is a candidate for intensive chemotherapy.
• Newly diagnosed Ph+ ALL.
• Written informed consent prior to any screening procedures. Permitted exceptions are that the diagnostic marrow exam/peripheral blood/nodal biopsy tests confirming Ph+ B-Cell ALL, as well as pre-induction cardiac workup (EKG/TTE/MUGA), may be performed prior to the patient providing written informed consent if these tests are within 14 days of enrollment.
• Patient able to give informed consent.

• B-cell Acute Lymphoblastic Leukemia with BCR-ABL1, i.e., Philadelphia chromosome-positive (Ph+) ALL.

  • B-Cell lineage determined by standard flow cytometry/IHC
  • Ph+ by cytogenetics (karyotype/FISH) and/or molecular (BCR-ABL1 transcripts)
  • Determined in CLIA-certified laboratory

• Previously untreated, except for below allowances in a recent diagnosis and up until 48 hours after starting trial therapy:

  • Corticosteroids
  • Hydroxyurea
  • Leukapheresis

Key Exclusion Criteria

• Any of the following subtypes of ALL:

  • Ph-negative B-Cell ALL.
  • T-Cell ALL.
  • Relapsed Ph+ ALL.
  • Lymphoid blast crisis of chronic myeloid leukemia (CML).
  • Mature B-Cell (Burkitt's) ALL.
• Clinical signs of CNS disease.
• Active ALL in CNS or testes.
• Estimated Glomerular Filtration Rate (eGFR) by MDRD formula and calculated creatinine clearance (CrCl), based on a 24-hour urine collection, < 30 mL/min-unless related to ALL/tumor lysis syndrome and able to be corrected.
• Total Bilirubin > 2x ULN; AST/ALT > 10x ULN, unless related to ALL liver infiltration.
• Patients with known history of HIV, Hepatitis B, or Hepatitis C.
• Pre-treatment QTcF > 480 msecs.
• Left Ventricular Ejection Fraction < 45%. If an initial TTE demonstrates LVEF < 45%, a confirmatory MUGA should be performed to confirm LVEF is < 45% prior to excluding the patient. Both a TTE and a MUGA with LVEF < 45% are needed to exclude a patient. Either a TTE or MUGA alone, if LVEF is ≥ 45%, is sufficient to include a patient.

• Have significant or active cardiovascular disease, specifically including but not restricted to:

  • Known prior type 1 (thrombotic) myocardial infarction (type 2 myocardial infarction/demand ischemia is not necessarily excluded).
  • History of clinically significant atrial arrhythmia or any ventricular arrhythmia.
  • Unstable angina within the last 12 months.
  • Congestive heart failure within the last 12 months.
  • Currently uncontrolled hypertension (≥ Grade 3; or systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg).
• Acute pancreatitis within the last year or a history of chronic pancreatitis.
• Have malabsorption syndrome or other gastrointestinal illness that could affect the absorption of orally administered chemotherapy.
• Ongoing uncontrolled severe nausea or vomiting.

• History of a significant bleeding disorder unrelated to ALL, including:

  • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease).
  • Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
• Taking any medications or herbal supplements that are known to be strong inhibitors or inducers of CYP3A4 within at least 7 days or 5 half-lives (whichever is longer) before the first dose of study chemotherapy on day 1 of Remission Induction Phase I (RIP1).
• Active malignancy requiring treatment, other than ALL, within two years prior to start of treatment, with the exception of basal cell or squamous cell carcinoma of the skin, colon polyp, carcinoma in situ of the cervix, or DCIS or LCIS of the breast.
• Active uncontrolled infection, any other concurrent disease, or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator.
• Pregnant women or women who are breast-feeding
• Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and up until 30 days following the end of trial therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: BFM + Tyrosine Kinase Inhibitor; This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.

Drug: Dasatinib; By mouth; Drug: Ponatinib; By mouth; Drug: Berlin-Frankfurt-Münster Chemotherapy; with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone; Drug: Methotrexate and Cytarabine; Intrathecal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of complete molecular remission (CMR) at the end of one cycle of Dasatinib + BFM	CMR will be assessed by minimal residual disease (MRD)-negative status, using quantitative reverse transcription-polymerase chain reaction (RT-qPCR) analysis from bone marrow aspirates, after 1 cycle of induction therapy with Berlin-Frankfurt-Münster (BFM) protocol and Dasatinib.	Post day 36; up to day 43

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of Adverse Events related to Dasatinib and Ponatinib	Per NCI CTCAE v5.0 toxicity data, specifically: for dasatinib: pulmonary hypertension (any grade) or grade ≥ 3 serositis/volume overload.; for ponatinib: arterial embolism (any grade) and grade ≥ 3 venous thromboembolism, heart failure, or pancreatitis	30 days after last treatment, up to approximately 3 years
Percentage of participants who begin ponatinib post-induction that complete at least one cycle.	Feasibility will be assessed by the percentage, among patients who begin the ponatinib post-induction regimen, that complete at least one cycle. Completion is defined as the ability to tolerate ≥ 80% dose intensity of all prescribed anti-cancer agents per cycle of ponatinib initiated.	At 18 weeks
Complete hematologic (morphologic) remission (CHR) rate after induction	Bone marrow assessed by morphologic review of both the aspirate smear and core biopsy	After Remission Induction Phase I and at end of study treatment, up to approximately 3 years
Complete cytogenic remission (CCyR) rate post induction	Bone marrow aspirate assessed by karyotype and/or fluorescence in situ hybridization (FISH).	After Remission Induction Phase I and at end of study treatment, up to approximately 3 years
Complete molecular remission (CMR) rate	Bone marrow aspirate analyzed by RT-qPCR.	After Remission Induction Phase I and at end of study treatment, up to approximately 3 years
Disease-free survival (DFS)	Disease-Free Survival (DFS) is defined as the duration of time from attainment of CR (morphologic remission, hematologic remission, etc) to Morphologic Relapse (Relapsed Disease) or Death.	up to five years after end of study treatment (approximately 8 years)
Overall survival (OS).	Overall Survival (OS) is defined as the length of time from the date of diagnosis that patients diagnosed with the disease are still alive.	up to five years after end of study treatment (approximately 8 years)

Collaborators and Investigators

• Sponsor: University of Michigan Rogel Cancer Center
• Collaborators: Takeda
• Investigators: Principal Investigator: Patrick Burke, MD, University of Michigan

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): January 1, 2029

Study Registration Dates

• First Submitted: April 5, 2021
• First Submitted That Met QC Criteria: April 9, 2021
• First Posted (Actual): April 14, 2021

Study Record Updates

• Last Update Posted (Actual): February 22, 2024
• Last Update Submitted That Met QC Criteria: February 20, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Acute Lymphoblastic Leukemia; Dasatinib; Ponatinib; Philadelphia chromosome
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Chromosome Aberrations; Translocation, Genetic; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Philadelphia Chromosome; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Protein Kinase Inhibitors; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Cytarabine; Methotrexate; Ponatinib; Dasatinib
• Other Study ID Numbers: UMCC 2018.144; HUM00171952 (Other Identifier: University of Michigan)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No